vs

Side-by-side financial comparison of CMB.TECH NV (CMBT) and PERRIGO Co plc (PRGO). Click either name above to swap in a different company.

PERRIGO Co plc is the larger business by last-quarter revenue ($1.1B vs $592.8M, roughly 1.9× CMB.TECH NV). CMB.TECH NV runs the higher net margin — 32.3% vs -127.8%, a 160.1% gap on every dollar of revenue. On growth, PERRIGO Co plc posted the faster year-over-year revenue change (-2.5% vs -34.6%).

CMB.TECH, before October 2024 known as Euronav, is a crude oil tanker transport company, which consists of VLCCs, Suezmaxes and FSOs.

Perrigo Company plc is an American Irish-registered manufacturer of private label over-the-counter pharmaceuticals, and while 70% of Perrigo's net sales are from the U.S. healthcare system, Perrigo is legally headquartered in Ireland for tax purposes, which accounts for 0.60% of net sales. In 2013, Perrigo completed the sixth-largest US corporate tax inversion in history when it reregistered its tax status to Ireland to avoid U.S. corporate taxes. Perrigo maintains its corporate headquarters ...

CMBT vs PRGO — Head-to-Head

Bigger by revenue
PRGO
PRGO
1.9× larger
PRGO
$1.1B
$592.8M
CMBT
Growing faster (revenue YoY)
PRGO
PRGO
+32.0% gap
PRGO
-2.5%
-34.6%
CMBT
Higher net margin
CMBT
CMBT
160.1% more per $
CMBT
32.3%
-127.8%
PRGO

Income Statement — Q4 FY2024 vs Q4 FY2025

Metric
CMBT
CMBT
PRGO
PRGO
Revenue
$592.8M
$1.1B
Net Profit
$191.2M
$-1.4B
Gross Margin
32.6%
Operating Margin
46.4%
-116.0%
Net Margin
32.3%
-127.8%
Revenue YoY
-34.6%
-2.5%
Net Profit YoY
-63.3%
-3093.9%
EPS (diluted)
$1.01
$-10.23

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
CMBT
CMBT
PRGO
PRGO
Q4 25
$1.1B
Q3 25
$1.0B
Q2 25
$1.1B
Q1 25
$1.0B
Q4 24
$592.8M
$1.1B
Q3 24
$1.1B
Q2 24
$1.1B
Q1 24
$1.1B
Net Profit
CMBT
CMBT
PRGO
PRGO
Q4 25
$-1.4B
Q3 25
$7.5M
Q2 25
$-8.4M
Q1 25
$-6.4M
Q4 24
$191.2M
$-44.4M
Q3 24
$-21.0M
Q2 24
$-108.4M
Q1 24
$2.0M
Gross Margin
CMBT
CMBT
PRGO
PRGO
Q4 25
32.6%
Q3 25
36.1%
Q2 25
34.4%
Q1 25
37.6%
Q4 24
33.9%
Q3 24
37.2%
Q2 24
37.0%
Q1 24
33.1%
Operating Margin
CMBT
CMBT
PRGO
PRGO
Q4 25
-116.0%
Q3 25
7.0%
Q2 25
4.3%
Q1 25
4.5%
Q4 24
46.4%
10.0%
Q3 24
7.4%
Q2 24
-2.5%
Q1 24
-5.1%
Net Margin
CMBT
CMBT
PRGO
PRGO
Q4 25
-127.8%
Q3 25
0.7%
Q2 25
-0.8%
Q1 25
-0.6%
Q4 24
32.3%
-3.9%
Q3 24
-1.9%
Q2 24
-10.2%
Q1 24
0.2%
EPS (diluted)
CMBT
CMBT
PRGO
PRGO
Q4 25
$-10.23
Q3 25
$0.05
Q2 25
$-0.06
Q1 25
$-0.05
Q4 24
$1.01
$-0.32
Q3 24
$-0.15
Q2 24
$-0.79
Q1 24
$0.01

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
CMBT
CMBT
PRGO
PRGO
Cash + ST InvestmentsLiquidity on hand
$38.9M
Total DebtLower is stronger
$2.6B
Stockholders' EquityBook value
$1.2B
$2.9B
Total Assets
$3.9B
$8.5B
Debt / EquityLower = less leverage
2.20×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
CMBT
CMBT
PRGO
PRGO
Q4 25
Q3 25
$432.1M
Q2 25
$454.2M
Q1 25
$409.9M
Q4 24
$38.9M
$558.8M
Q3 24
$1.5B
Q2 24
$542.8M
Q1 24
$658.5M
Total Debt
CMBT
CMBT
PRGO
PRGO
Q4 25
Q3 25
Q2 25
Q1 25
Q4 24
$2.6B
Q3 24
Q2 24
Q1 24
Stockholders' Equity
CMBT
CMBT
PRGO
PRGO
Q4 25
$2.9B
Q3 25
$4.4B
Q2 25
$4.5B
Q1 25
$4.4B
Q4 24
$1.2B
$4.3B
Q3 24
$4.6B
Q2 24
$4.5B
Q1 24
$4.7B
Total Assets
CMBT
CMBT
PRGO
PRGO
Q4 25
$8.5B
Q3 25
$10.1B
Q2 25
$10.1B
Q1 25
$9.8B
Q4 24
$3.9B
$9.6B
Q3 24
$11.2B
Q2 24
$10.4B
Q1 24
$10.6B
Debt / Equity
CMBT
CMBT
PRGO
PRGO
Q4 25
Q3 25
Q2 25
Q1 25
Q4 24
2.20×
Q3 24
Q2 24
Q1 24

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
CMBT
CMBT
PRGO
PRGO
Operating Cash FlowLast quarter
$204.4M
$175.4M
Free Cash FlowOCF − Capex
$148.6M
FCF MarginFCF / Revenue
13.4%
Capex IntensityCapex / Revenue
2.4%
Cash ConversionOCF / Net Profit
1.07×
TTM Free Cash FlowTrailing 4 quarters
$145.1M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
CMBT
CMBT
PRGO
PRGO
Q4 25
$175.4M
Q3 25
$51.7M
Q2 25
$75.9M
Q1 25
$-64.5M
Q4 24
$204.4M
$312.6M
Q3 24
$42.2M
Q2 24
$9.5M
Q1 24
$-1.4M
Free Cash Flow
CMBT
CMBT
PRGO
PRGO
Q4 25
$148.6M
Q3 25
$29.8M
Q2 25
$56.7M
Q1 25
$-90.0M
Q4 24
$274.9M
Q3 24
$15.1M
Q2 24
$-18.9M
Q1 24
$-26.5M
FCF Margin
CMBT
CMBT
PRGO
PRGO
Q4 25
13.4%
Q3 25
2.9%
Q2 25
5.4%
Q1 25
-8.6%
Q4 24
24.2%
Q3 24
1.4%
Q2 24
-1.8%
Q1 24
-2.4%
Capex Intensity
CMBT
CMBT
PRGO
PRGO
Q4 25
2.4%
Q3 25
2.1%
Q2 25
1.8%
Q1 25
2.4%
Q4 24
3.3%
Q3 24
2.5%
Q2 24
2.7%
Q1 24
2.3%
Cash Conversion
CMBT
CMBT
PRGO
PRGO
Q4 25
Q3 25
6.89×
Q2 25
Q1 25
Q4 24
1.07×
Q3 24
Q2 24
Q1 24
-0.70×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

CMBT
CMBT

Segment breakdown not available.

PRGO
PRGO

Consumer Self Care Americas$697.0M63%
Digestive Health$123.9M11%
Nutrition$108.3M10%
Healthy Lifestyle$94.8M9%
Pain And Sleep Aids$87.1M8%

Related Comparisons